What is required for patients receiving Ziprasidone (Geodon) due to its potential cardiac side effects?

Patients receiving Ziprasidone (Geodon) require a baseline electrocardiogram (ECG) and observation for arrhythmias because this medication can cause significant cardiac side effects, particularly prolongation of the QT interval. The QT interval refers to the time it takes for the heart's electrical system to reset after each heartbeat, and its prolongation can lead to serious arrhythmias, such as Torsades de Pointes, which can be life-threatening.

Before initiating treatment with Ziprasidone, obtaining a baseline ECG allows healthcare providers to assess the QT interval and establish a reference point to monitor for any changes throughout treatment. Continued observation for arrhythmias is necessary because symptoms like palpitations or syncope may indicate the development of a serious cardiac issue as a result of the medication. This proactive approach is essential in ensuring patient safety and managing any potential side effects associated with Ziprasidone.

The incorrect choices include options that do not address the specific cardiac monitoring needs associated with Ziprasidone. Routine blood pressure monitoring and weekly liver function tests are not routinely indicated as part of the monitoring protocols for this medication's specific risks.